SCHEMBL624636

SCHEMBL624636

CC(C)COc1cc(N2CCN(C(=O)c3nc4ccccc4s3)CC2)ncn1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
TSHR P16473 3/20 0.58
HSD17B10 Q99714 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.54
RAB9A P51151 3/20 0.49
HPGD P15428 1/20 0.49
LMNA P02545 3/20 0.47
MAPT P10636 3/20 0.47
TP53 P04637 1/20 0.47
HTT P42858 1/20 0.43
NAAA Q02083 1/20 0.42
NPC1 O15118 3/20 0.42
ALOX15 P16050 1/20 0.41
CASP1 P29466 1/20 0.41
RBP4 P02753 1/20 0.41
PDE2A O00408 1/20 0.41
CYP26A1 O43174 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623703 0.85 HRH4 (0.54) LMNAMAPTTP53
SCHEMBL623189 0.81 PTK2 (0.51) TSHRPDE2A
SCHEMBL624496 0.81 TSHR (0.53) ALDH1A1TSHRSMN1; SMN2RAB9AMAPT
SCHEMBL624539 0.80 MGLL (0.44) ALDH1A1SMN1; SMN2LMNAMAPTTP53
SCHEMBL624477 0.80 MEN1 (0.45) ALDH1A1TSHRHSD17B10SMN1; SMN2HPGD
SCHEMBL623239 0.79 ALDH1A1 (0.52) ALDH1A1TSHRSMN1; SMN2RAB9ALMNA
SCHEMBL623777 0.78 P2RY12 (0.46) TSHRHSD17B10RAB9ALMNATP53
SCHEMBL623165 0.78 CCKAR (0.44) ALDH1A1TSHR
SCHEMBL622565 0.78 MGLL (0.43) ALDH1A1TSHRHSD17B10SMN1; SMN2RAB9A
SCHEMBL623195 0.78 MGLL (0.41) ALDH1A1TSHRHSD17B10SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G ALDH1A1 2071/4885TSHR 1643/4885HSD17B10 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.